Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7-3.9 million persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical monitoring) and treatment. CDC estimates that although persons born during 1945-1965 comprise an estimated 27% of the population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associated mortality, and are at greatest risk for hepatocellular carcinoma and other HCV-related liver disease. With the advent of new therapies that can halt disease progression and provide a virologic cure (i.e., sustained viral clearance following completion of treatment) in most persons, targeted testing and linkage to care for infected persons in this birth cohort is expected to reduce HCV-related morbidity and mortality. CDC is augmenting previous recommendations for HCV testing (CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47[No. RR-19]) to recommend one-time testing without prior ascertainment of HCV risk for persons born during 1945-1965, a population with a disproportionately high prevalence of HCV infection and related disease. Persons identified as having HCV infection should receive a brief screening for alcohol use and intervention as clinically indicated, followed by referral to appropriate care for HCV infection and related conditions. These recommendations do not replace previous guidelines for HCV testing that are based on known risk factors and clinical indications. Rather, they define an additional target population for testing: persons born during 1945-1965. CDC developed these recommendations with the assistance of a work group representing diverse expertise and perspectives. The recommendations are informed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, an approach that provides guidance and tools to define the research questions, conduct the systematic review, assess the overall quality of the evidence, and determine strength of the recommendations. This report is intended to serve as a resource for health-care professionals, public health officials, and organizations involved in the development, implementation, and evaluation of prevention and clinical services. These recommendations will be reviewed every 5 years and updated to include advances in the published evidence.

[1]  K. Migita,et al.  Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus , 2010, Journal of Gastroenterology.

[2]  H. Margolis,et al.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .

[3]  Yasuyuki Arakawa,et al.  Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.

[4]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[5]  R. D. Bruce,et al.  Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users , 2006, Journal of acquired immune deficiency syndromes.

[6]  Angelique Zeringue,et al.  Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. , 2011, Gastroenterology.

[7]  Rachel S Tocco,et al.  Public health impact of antiviral therapy for hepatitis C in the United States , 2009, Hepatology.

[8]  T. Therneau,et al.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[10]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[11]  A. Outlaw,et al.  Characteristics Associated With Retention Among African American and Latino Adolescent HIV-Positive Men: Results From the Outreach, Care, and Prevention to Engage HIV-Seropositive Young MSM of Color Special Project of National Significance Initiative , 2010, Journal of acquired immune deficiency syndromes.

[12]  T. Nakajima,et al.  Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  S. Sonnad,et al.  Management of hepatitis C patients by primary care physicians in the USA: results of a national survey , 2001, Journal of viral hepatitis.

[14]  C. Cunningham,et al.  Medical and Support Service Utilization in a Medical Program Targeting Marginalized HIV-infected Individuals , 2008, Journal of health care for the poor and underserved.

[15]  T. Asselah,et al.  Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[16]  P. Patel,et al.  Hepatitis C virus transmission at an outpatient hemodialysis unit--New York, 2001-2008. , 2009, MMWR. Morbidity and mortality weekly report.

[17]  D. Sinn,et al.  Disease progression and the risk factor analysis for chronic hepatitis C , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[18]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[19]  Gordon H Guyatt,et al.  GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.

[20]  H. Thomas,et al.  Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications , 2007, Journal of viral hepatitis.

[21]  Michael J. O'Grady,et al.  Economic model of a birth cohort screening program for hepatitis C virus , 2012, Hepatology.

[22]  Gerald Gartlehner,et al.  [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[23]  A. Sanyal The Institute of Medicine report on viral hepatitis: A call to action , 2010, Hepatology.

[24]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[25]  B. Graubard,et al.  Data and trends in cancer screening in the United States , 2010, Cancer.

[26]  D. Rein,et al.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[28]  W P Havens,et al.  Viral hepatitis. , 1970, The Medical clinics of North America.

[29]  R. Hays,et al.  Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.

[30]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  Shimul A. Shah,et al.  Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? , 2011, Expert review of gastroenterology & hepatology.

[32]  T. Poynard [Hepatitis C: natural history, biology, treatment monitoring]. , 1999, Pathologie-biologie.

[33]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[34]  N. Enomoto,et al.  Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection , 2010, Hepatology.

[35]  Hirokazu Takahashi,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011, Journal of gastroenterology.

[36]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[37]  S. Holmberg,et al.  Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care , 2005, AIDS.

[38]  G. Foster,et al.  Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing , 2010, Transfusion.

[39]  Sheng-Nan Lu,et al.  Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy , 2011, International journal of cancer.

[40]  R. Chou,et al.  Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force , 2004, Annals of Internal Medicine.

[41]  J. Fleishman,et al.  Effect of Case Management on Unmet Needs and Utilization of Medical Care and Medications among HIV-Infected Persons , 2001, Annals of Internal Medicine.

[42]  G. Norkrans,et al.  Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection , 2002, Journal of viral hepatitis.

[43]  Y. Imai,et al.  Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[44]  M. Ghany,et al.  An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[45]  Gordon H Guyatt,et al.  GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.

[46]  Mark E. Johnson,et al.  HIV Risk Behavior Self-Report Reliability at Different Recall Periods , 2009, AIDS and Behavior.

[47]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[48]  K. Mayer Introduction: Linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  J. Tulsky,et al.  The medical management of opioid dependence in HIV primary care settings , 2006, Current HIV/AIDS reports.

[50]  Hirokazu TakahashiToshihiko,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011 .

[51]  R. Garfein,et al.  Self-Reported Hepatitis C Virus Antibody Status and Risk Behavior in Young Injectors , 2006, Public health reports.

[52]  M. Dembert,et al.  Principles and practices of screening for disease. , 1988, Military medicine.

[53]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[54]  R. Merion,et al.  Liver and Intestine Transplantation in the United States, 1997–2006 , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[55]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  Peter J. Richardson,et al.  Antiviral Treatment for Hepatitis C Virus is Associated With a Reduced Risk of Hepatocellular Carcinoma in a National Cohort of U.S. Veterans , 2011 .

[57]  E. Schiff,et al.  Hepatitis C virus infection in USA: an estimate of true prevalence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[58]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[59]  S. Sonnad,et al.  Current practice patterns of primary care physicians in the management of patients with hepatitis C , 1999, Hepatology.

[60]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[61]  B. Bacon,et al.  Chronic hepatitis C: an age wave of disease burden. , 2005, The American journal of managed care.

[62]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[63]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[64]  E. Schiff,et al.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.

[65]  F. Altice,et al.  Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  E. Parise,et al.  Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[67]  R. Garfein,et al.  Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. , 2011, The Journal of infectious diseases.

[68]  V. Miller,et al.  Buprenorphine and HIV primary care: new opportunities for integrated treatment. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  M. Alter,et al.  Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. , 2011, Archives of internal medicine.

[70]  H. Marusawa,et al.  Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study , 2012, Journal of Gastroenterology.

[71]  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[72]  M. Golden,et al.  Patient acceptance of universal screening for hepatitis C virus infection , 2011, BMC infectious diseases.

[73]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[74]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[75]  Z. Younossi,et al.  Screening for hepatitis B, C and non‐alcoholic fatty liver disease: a survey of community‐based physicians , 2009, Alimentary pharmacology & therapeutics.

[76]  Sanjeev Arora,et al.  Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.

[77]  F. Molitor,et al.  Locating and linking to medical care HIV-positive persons without a history of care: Findings from the California Bridge Project , 2006, AIDS care.

[78]  Gerald Gartlehner,et al.  [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[79]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[80]  A. Clouston,et al.  Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis , 1999, Hepatology.

[81]  M. Alter,et al.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[82]  Yoshiyuki Suzuki,et al.  Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. , 2010, The American journal of medicine.

[83]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[84]  H. El‐Serag Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[85]  ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. , 2007, Obstetrics and gynecology.

[86]  J. Ferrante,et al.  Family physicians' knowledge and screening of chronic hepatitis and liver cancer. , 2008, Family medicine.

[87]  L. Rodrigo,et al.  Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.

[88]  C. Christiansen,et al.  Hepatitis C testing practices and prevalence in a high‐risk urban ambulatory care setting , 2011, Journal of viral hepatitis.

[89]  R. D. Bruce,et al.  Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users , 2010, AIDS.